Immunogenicity and characterization of WRSF2G11: A second generation live attenuated Shigella flexneri 2a vaccine strain

Vaccine

Volumn 25, Issue 12, 2007, Pages 2269-2278

  Ranallo, Ryan T ^a   Thakkar, Sejal ^a   Chen, Qing ^a   Venkatesan, Malabi M ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Bacteria; Live; Shigella; Vaccine

Indexed keywords

ENTEROTOXIN; LIVE VACCINE; RECOMBINASE; SHIGELLA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; GENE DELETION; GUINEA PIG; HELA CELL; IMMUNIZATION; IMMUNOGENICITY; MALE; NONHUMAN; PRIORITY JOURNAL; SHIGELLA FLEXNERI; SHIGELLOSIS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; DNA-BINDING PROTEINS; DYSENTERY, BACILLARY; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GUINEA PIGS; HELA CELLS; HUMANS; IMMUNITY, MUCOSAL; SHIGELLA FLEXNERI; SHIGELLA VACCINES; TRANSCRIPTION FACTORS; VACCINES, ATTENUATED;

EID: 33846885007     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.067     Document Type: Article

References (64)

1. Niyogi S.K. Shigellosis. J Microbiol 43 2 (2005) 133-143
2. von Seidlein L., Kim D.R., Ali M., Lee H., Wang X., Thiem V.D., et al. A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: disease burden, clinical manifestations, and microbiology. PLoS Med 3 9 (2006)
3. Parsot C. Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors. FEMS Microbiol Lett 252 1 (2005) 11-18
4. Jennison A.V., and Verma N.K. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol Rev 28 1 (2004) 43-58
5. Cossart P., and Sansonetti P.J. Bacterial invasion: the paradigms of enteroinvasive pathogens. Science 304 5668 (2004) 242-248
6. Lett M.C., Sasakawa C., Okada N., Sakai T., Makino S., Yamada M., et al. virG, a plasmid-coded virulence gene of Shigella flexneri: identification of the virG protein and determination of the complete coding sequence. J Bacteriol 171 1 (1989) 353-359
7. Bernardini M.L., Mounier J., d'Hauteville H., Coquis-Rondon M., and Sansonetti P.J. Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin. Proc Natl Acad Sci USA 86 10 (1989) 3867-3871
8. Suzuki T., Lett M.C., and Sasakawa C. Extracellular transport of VirG protein in Shigella. J Biol Chem 270 52 (1995) 30874-30880
9. Suzuki T., Saga S., and Sasakawa C. Functional analysis of Shigella VirG domains essential for interaction with vinculin and actin-based motility. J Biol Chem 271 36 (1996) 21878-21885
10. Perdomo O.J., Cavaillon J.M., Huerre M., Ohayon H., Gounon P., and Sansonetti P.J. Acute inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis. J Exp Med 180 4 (1994) 1307-1319
11. Mandic-Mulec I., Weiss J., and Zychlinsky A. Shigella flexneri is trapped in polymorphonuclear leukocyte vacuoles and efficiently killed. Infect Immun 65 1 (1997) 110-115
12. Samandari T., Kotloff K.L., Losonsky G.A., Picking W.D., Sansonetti P.J., Levine M.M., et al. Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol 164 4 (2000) 2221-2232
13. Kotloff K.L., Nataro J.P., Losonsky G.A., Wasserman S.S., Hale T.L., Taylor D.N., et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 13 16 (1995) 1488-1494
14. Munoz C., Baqar S., van de Verg L., Thupari J., Goldblum S., Olson J.G., et al. Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances. Am J Trop Med Hyg 53 1 (1995) 47-54
15. Islam D., Wretlind B., Ryd M., Lindberg A.A., and Christensson B. Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis. Infect Immun 63 5 (1995) 2054-2061
16. Turbyfill K.R., Hartman A.B., and Oaks E.V. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect Immun 68 12 (2000) 6624-6632
17. Oaks E.V., and Turbyfill K.R. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine 24 13 (2006) 2290-2301
18. Taylor D.N., Trofa A.C., Sadoff J., Chu C., Bryla D., Shiloach J., et al. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun 61 9 (1993) 3678-3687
19. Cohen D., Ashkenazi S., Green M.S., Gdalevich M., Robin G., Slepon R., et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349 9046 (1997) 155-159
20. Levenson V.J., Mallett C.P., and Hale T.L. Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine. Infect Immun 63 7 (1995) 2762-2765
21. Orr N., Katz D.E., Atsmon J., Radu P., Yavzori M., Halperin T., et al. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 73 12 (2005) 8027-8032
22. Li A., Pal T., Forsum U., and Lindberg A.A. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers. Vaccine 10 6 (1992) 395-404
23. Li A., Karnell A., Huan P.T., Cam P.D., Minh N.B., Tram L.N., et al. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers. Vaccine 11 2 (1993) 180-189
24. Li A., Cam P.D., Islam D., Minh N.B., Huan P.T., Rong Z.C., et al. Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124. J Infect 28 1 (1994) 11-23
25. Kotloff K.L., Taylor D.N., Sztein M.B., Wasserman S.S., Losonsky G.A., Nataro J.P., et al. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 70 4 (2002) 2016-2021
26. Kotloff K.L., Pasetti M.F., Barry E.M., Nataro J.P., Wasserman S.S., Sztein M.B., et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis 190 10 (2004) 1745-1754
27. Kotloff K.L., Noriega F.R., Samandari T., Sztein M.B., Losonsky G.A., Nataro J.P., et al. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun 68 3 (2000) 1034-1039
28. Kotloff K.L., Noriega F., Losonsky G.A., Sztein M.B., Wasserman S.S., Nataro J.P., et al. Safety, immunogenicity and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun 64 11 (1996) 4542-4548
29. Kotloff K.L., Losonsky G.A., Nataro J.P., Wasserman S.S., Hale T.L., Taylor D.N., et al. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 13 5 (1995) 495-502
30. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 72 2 (2004) 923-930
31. Karnell A., Li A., Zhao C.R., Karlsson K., Nguyen B.M., and Lindberg A.A. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 13 1 (1995) 88-99
32. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67 7 (1999) 3437-3443
33. McKenzie R., Walker R.I., Nabors G.S., Verg L.L., Carpenter C., Gomes G., et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine (2005)
34. DuPont H.L., Hornick R.B., Snyder M.J., Libonati J.P., Formal S.B., and Gangarosa E.J. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis 125 1 (1972) 12-16
35. Herrington D.A., Van de Verg L., Formal S.B., Hale T.L., Tall B.D., Cryz S.J., et al. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8 4 (1990) 353-357
36. Ferreccio C., Prado V., Ojeda A., Cayyazo M., Abrego P., Guers L., et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol 134 6 (1991) 614-627
37. Cohen D., Green M.S., Block C., Slepon R., and Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol 29 2 (1991) 386-389
38. Taylor D.N., Echeverria P., Pal T., Sethabutr O., Saiborisuth S., Sricharmorn S., et al. The role of Shigella spp., enteroinvasive Escherichia coli, and other enteropathogens as causes of childhood dysentery in Thailand. J Infect Dis 153 6 (1986) 1132-1138
39. Keren D.F., Holt P.S., Collins H.H., Gemski P., and Formal S.B. The role of Peyer's patches in the local immune response of rabbit ileum to live bacteria. J Immunol 120 6 (1978) 1892-1896
40. Venkatesan M.M., and Ranallo R.T. Live attenuate Shigella vaccines. Expert Rev Vaccines 5 5 (2006) 669-686
41. Nataro J.P., Seriwatana J., Fasano A., Maneval D.R., Guers L.D., Noriega F., et al. Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun 63 12 (1995) 4721-4728
42. Fasano A., Noriega F.R., Maneval Jr. D.R., Chanasongcram S., Russell R., Guandalini S., et al. Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest 95 6 (1995) 2853-2861
43. Fasano A., Noriega F.R., Liao F.M., Wang W., and Levine M.M. Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo. Gut 40 4 (1997) 505-511
44. Vargas M., Gascon J., Jimenez De Anta M.T., and Vila J. Prevalence of Shigella enterotoxins 1 and 2 among Shigella strains isolated from patients with traveler's diarrhea. J Clin Microbiol 37 11 (1999) 3608-3611
45. Yavzori M., Cohen D., and Orr N. Prevalence of the genes for shigella enterotoxins 1 and 2 among clinical isolates of shigella in Israel. Epidemiol Infect 128 3 (2002) 533-535
46. Al-Hasani K., Rajakumar K., Bulach D., Robins-Browne R., Adler B., and Sakellaris H. Genetic organization of the she pathogenicity island in Shigella flexneri 2a. Microb Pathog 30 1 (2001) 1-8
47. DuPont H.L., Hornick R.B., Dawkins A.T., Snyder M.J., and Formal S.B. The response of man to virulent Shigella flexneri 2a. J Infect Dis 119 3 (1969) 296-299
48. Barzu S., Fontaine A., Sansonetti P., and Phalipon A. Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier. Infect Immun 64 4 (1996) 1190-1196
49. Ranallo R.T., Barnoy S., Thakkar S., Urick T., and Venkatesan M.M. Developing live Shigella vaccines using lambda Red recombineering. FEMS Immunol Med Microbiol 47 3 (2006) 462-469
50. Cherepanov P.P., and Wackernagel W. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158 1 (1995) 9-14
51. Ranallo R.T., Fonseka C.P., Cassels F., Srinivasan J., and Venkatesan M.M. Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 73 1 (2005) 258-267
52. Mills J.A., Buysse J.M., and Oaks E.V. Shigella flexneri invasion plasmid antigens B and C: epitope location and characterization with monoclonal antibodies. Infect Immun 56 11 (1988) 2933-2941
53. Elsinghorst E.A. Measurement of invasion by gentamicin resistance. Methods Enzymol 236 (1994) 405-420
54. Fernandez-Prada C.M., Hoover D.L., Tall B.D., and Venkatesan M.M. Human monocyte-derived macrophages infected with virulent Shigella flexneri in vitro undergo a rapid cytolytic event similar to oncosis but not apoptosis. Infect Immun 65 4 (1997) 1486-1496
55. Fernandez-Prada C.M., Hoover D.L., Tall B.D., Hartman A.B., Kopelowitz J., and Venkatesan M.M. Shigella flexneri IpaH(7.8) facilitates escape of virulent bacteria from the endocytic vacuoles of mouse and human macrophages. Infect Immun 68 6 (2000) 3608-3619
56. Sereny B. Experimental shigella keratoconjunctivitis; a preliminary report. Acta Microbiol Acad Sci Hung 2 3 (1955) 293-296
57. Sansonetti P.J., and Arondel J. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7 5 (1989) 443-450
58. Kang H.Y., and Curtiss III R. Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization. FEMS Immunol Med Microbiol 37 2-3 (2003) 99-104
59. Hartman A.B., Powell C.J., Schultz C.L., Oaks E.V., and Eckels K.H. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect Immun 59 11 (1991) 4075-4083
60. Bernardini M.L., Arondel J., Martini I., Aidara A., and Sansonetti P.J. Parameters underlying successful protection with live attenuated mutants in experimental shigellosis. Infect Immun 69 2 (2001) 1072-1083
61. Buchrieser C., Glaser P., Rusniok C., Nedjari H., D'Hauteville H., Kunst F., et al. The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri. Mol Microbiol 38 4 (2000) 760-771
62. Venkatesan M.M., Goldberg M.B., Rose D.J., Grotbeck E.J., Burland V., and Blattner F.R. Complete DNA sequence and analysis of the large virulence plasmid of Shigella flexneri. Infect Immun 69 5 (2001) 3271-3285
63. Al-Hasani K., Henderson I.R., Sakellaris H., Rajakumar K., Grant T., Nataro J.P., et al. The sigA gene which is borne on the she pathogenicity island of Shigella flexneri 2a encodes an exported cytopathic protease involved in intestinal fluid accumulation. Infect Immun 68 5 (2000) 2457-2463
64. D'Hauteville H., Khan S., Maskell D.J., Kussak A., Weintraub A., Mathison J., et al. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 168 10 (2002) 5240-5251